⌕
Mineralys Therapeutics · MLYS · Nasdaq
Tenet 55 · Mixed
Compare
$14.48−0.34%At closeTenet 55 · Mixed
$14.48−0.05 (−0.34%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Mineralys Therapeutics (MLYS) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is MLYS's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Defense WorldNov 15, 2026 · 09:53 ET
87,400 Shares of Mineralys Therapeutics, Inc. $MLYS Acquired by ACT Capital Partners L.P.

ACT Capital Partners L.P. purchased a new stake in shares of Mineralys Therapeutics, Inc. (NASDAQ: MLYS) during a recent quarter, according to its most recent filing with the SEC. The institutional investor purchased 87,…

MLYS −0.3% todayRead at source ↗
● GlobeNewsWireNov 8, 2026 · 16:35 ETCOMPANY'S OWN WORDS
Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026

– In the largest long-term hypertension trial of an aldosterone synthase inhibitor to date, lorundrostat demonstrated sustained reduction in automated office systolic blood pressure (AOSBP) of 17.8 mmHg at Week 48 from L…

MLYS −0.3% todayRead at source ↗
● GlobeNewsWireNov 6, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in c…

MLYS −0.3% todayRead at source ↗
● Seeking AlphaNov 5, 2026 · 12:29 ET
Mineralys: Fairly Valued Near $17 As Baxfendy Launch Validates Slow ASI Ramp (Upgrade)

Mineralys Therapeutics is launching lorundrostat, a second-to-market ASI, with limited differentiation from BAXFENDY on efficacy or safety. MLYS faces AstraZeneca's entrenched cardiorenal franchise, restrictive payer pol…

MLYS −0.3% todayRead at source ↗
● MarketBeatNov 4, 2026 · 22:23 ET
What Mineralys Therapeutics (MLYS) Said on Its Q3 Earnings Call

Mineralys Therapeutics NASDAQ: MLYS is preparing to launch its hypertension drug candidate lorundrostat if it wins regulatory approval, with a U.S. Food and Drug Administration decision targeted for Dec. 22, executives s…

MLYS −0.3% todayRead at source ↗
● Seeking AlphaNov 4, 2026 · 20:24 ET
Mineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call Transcript

Mineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call Transcript…

MLYS −0.3% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

– Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 – – New analyses from the pivotal Launch-HTN trial showed 46% of participants with uncontrolled or resistant hyperte…

MLYS −0.3% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Mineralys Therapeutics to Participate in Upcoming Investor Conferences

RADNOR, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in c…

MLYS −0.3% todayRead at source ↗
● GlobeNewsWireOct 28, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026

RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in c…

MLYS −0.3% todayRead at source ↗
● GlobeNewsWireOct 28, 2026 · 07:05 ETCOMPANY'S OWN WORDS
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International

- Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks -…

MLYS −0.3% todayRead at source ↗
● GlobeNewsWireOct 22, 2026 · 18:40 ETCOMPANY'S OWN WORDS
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026

In the large, pivotal Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood pressure reductions in participants with and without CKD, with consistent reductions across Stages 1-3 CKD…

MLYS −0.3% todayRead at source ↗
● GlobeNewsWireOct 19, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats

RADNOR, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in c…

MLYS −0.3% todayRead at source ↗
● GlobeNewsWireOct 9, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of…

MLYS −0.3% todayRead at source ↗
● Defense WorldOct 4, 2026 · 08:02 ET
Mineralys (NASDAQ: MLYS) CEO sells 75,000 shares under prearranged plan

What happened Mineralys Therapeutics, Inc. (NASDAQ: MLYS) said Chief Executive Officer and director Jon Congleton sold 75,000 shares on 2026-09-30. The Form 4 says the shares changed hands at a weighted-average $25.46 ea…

MLYS −0.3% todayRead at source ↗
● GlobeNewsWireOct 2, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026

RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in c…

MLYS −0.3% todayRead at source ↗
● GlobeNewsWireOct 1, 2026 · 16:05 ET
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026

RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in c…

MLYS −0.3% todayRead at source ↗
● GlobeNewsWireSep 29, 2026 · 16:05 ET
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in …

MLYS −0.3% todayRead at source ↗
● Defense WorldSep 25, 2026 · 04:08 ET
Mineralys Therapeutics (NASDAQ:MLYS) Director Brian Taylor Slingsby Sells 104,320 Shares of Company Stock

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) Director Brian Slingsby sold 104,320 shares of the business's stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price o…

MLYS −0.3% todayRead at source ↗
● GlobeNewsWireSep 24, 2026 · 16:05 ET
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in …

MLYS −0.3% todayRead at source ↗
● GlobeNewsWireSep 23, 2026 · 16:05 ET
Mineralys Therapeutics' Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026

RADNOR, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in …

MLYS −0.3% todayRead at source ↗
● Defense WorldSep 23, 2026 · 05:12 ET
Mineralys Therapeutics (NASDAQ:MLYS) Insider Eric Warren Sells 7,438 Shares

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) insider Eric Warren sold 7,438 shares of the stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $28.12, for a tota…

MLYS −0.3% todayRead at source ↗
● GlobeNewsWireSep 21, 2026 · 16:05 ET
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in …

MLYS −0.3% todayRead at source ↗
● Defense WorldSep 20, 2026 · 05:23 ET
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Director Sells $85,740.00 in Stock

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) Director Daphne Karydas sold 3,000 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $28.58, for a…

MLYS −0.3% todayRead at source ↗
● GlobeNewsWireSep 9, 2026 · 16:05 ET
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in …

MLYS −0.3% todayRead at source ↗
● Defense WorldSep 7, 2026 · 04:18 ET
Greenland Capital Management LP Sells 53,500 Shares of Mineralys Therapeutics, Inc. $MLYS

Greenland Capital Management LP reduced its holdings in Mineralys Therapeutics, Inc. (NASDAQ: MLYS) by 64.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The ins…

MLYS −0.3% todayRead at source ↗

No upcoming events in the feeds.

NVDA33−0.4%
DLB4−3.8%
WDAY4−5.8%

Article counts from the last market-wide feed page, across every symbol we track and not just MLYS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.